Thursday, January 17, 2008

GenVec will save your life




"GenVec (GNVC) is a smallcap biotech trying to become a bigcap. Its lead product, TNFerade, is currently in a pivotal Phase II/III study [PACT] in locally advanced pancreatic cancer; Phase II studies are in progress in rectal cancer and melanoma, and Phase I/II studies are in progress in head and neck cancer. GenVec also uses its proprietary adenovector technology to develop vaccines for infectious diseases including HIV, malaria, seasonal and pandemic flu and foot and mouth disease. During GenVec's most recent discussions with the FDA, the FDA agreed to change the primary endpoint of the PACT trial to overall survival from one year survival. "

No comments: